The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC).

Naomi B. Haas

Consultant or Advisory Role - Boehringer Ingelheim; Boehringer Ingelheim; Dendreon; Dendreon; Novartis; Novartis; Pfizer (I)

Research Funding - GlaxoSmithKline

Judith Manola

No relevant relationships to disclose

Bonnie Ky

Research Funding - Pfizer

Keith T. Flaherty

No relevant relationships to disclose

Robert G. Uzzo

Honoraria - Pfizer; Pfizer

Christopher G. Wood

Consultant or Advisory Role - Pfizer

Honoraria - Pfizer

Christopher J Kane

Consultant or Advisory Role - Amgen; Janssen Pharmaceutical

Honoraria - Amgen; Janssen Pharmaceutical

Michael A. S. Jewett

Consultant or Advisory Role - Canadian Institutes of Health Research; GlaxoSmithKline; Novartis; Pfizer (U); Viventia Biotech

Honoraria - Canadian institute of health research; GlaxoSmithKline; Novartis; Pfizer

Research Funding - Canadian Institutes of Health Research; GlaxoSmithKline; Novartis; Pfizer

Michael B. Atkins

Consultant or Advisory Role - AVEO; Bristol-Myers Squibb; Genentech; Novartis; Prometheus; Wilex

Janice P. Dutcher

Consultant or Advisory Role - Pfizer; Prometheus

Honoraria - Bayer; Novartis; Pfizer; Prometheus

Research Funding - Bayer; Pfizer; Prometheus

Robert S. DiPaola

No relevant relationships to disclose